The Long YM Bio Nightmare Has Ended -- Happily.

Gilead acquires YM Bio for $510 million in cash to grow its cancer drug pipeline.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!